Search hospitals > Michigan > Troy
William Beaumont Hospital - Troy
Claim this profileTroy, Michigan 48085
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Prostate Cancer
Conducts research for Pancreatic Cancer
218 reported clinical trials
24 medical researchers
Summary
William Beaumont Hospital - Troy is a medical facility located in Troy, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer, Pancreatic Cancer and other specialties. William Beaumont Hospital - Troy is involved with conducting 218 clinical trials across 264 conditions. There are 24 research doctors associated with this hospital, such as Laura K. Gowans, Dana Zakalik, Andrew A. Muskovitz, and Daniel J. Krauss.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
2Lung Cancer
Global LeaderStage II
Stage I
Stage III
Top PIs
Laura K. GowansBeaumont Children's Hospital-Royal Oak6 years of reported clinical research
Studies Cancer
Studies Brain Tumor
41 reported clinical trials
96 drugs studied
Dana ZakalikBeaumont Hospital - Farmington Hills2 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
12 reported clinical trials
46 drugs studied
Andrew A. MuskovitzWilliam Beaumont Hospital-Royal Oak4 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
8 reported clinical trials
19 drugs studied
Daniel J. KraussWilliam Beaumont Hospital - Troy4 years of reported clinical research
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
6 reported clinical trials
30 drugs studied
Clinical Trials running at William Beaumont Hospital - Troy
Lung Cancer
Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Cancer
Prostate Cancer
Uterine Cancer
Breast cancer
Colorectal Cancer
Esophageal cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at William Beaumont Hospital - Troy?
William Beaumont Hospital - Troy is a medical facility located in Troy, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer, Pancreatic Cancer and other specialties. William Beaumont Hospital - Troy is involved with conducting 218 clinical trials across 264 conditions. There are 24 research doctors associated with this hospital, such as Laura K. Gowans, Dana Zakalik, Andrew A. Muskovitz, and Daniel J. Krauss.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.